Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences

This article was originally published in The Pink Sheet Daily

Executive Summary

InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.

You may also be interested in...



Product Briefs: IPF Breakthroughs, Bigger Labels For Velcade And Lymphoseek, Acura Appeal Denied

Roche’s Esbriet and Boehringer’s Ofev become the first drugs approved by FDA for idiopathic pulmonary fibrosis; Velcade approved for first-line mantle cell lymphoma; Lymphoseek cleared for solid tumors; Acura mulls next steps after losing appeal on abuse-deterrent claim for Vycavert.

It’s A First (And Second) For IPF: Two Drugs Approved By FDA

FDA approved the first two drugs for the fatal lung disease idiopathic pulmonary fibrosis: Roche’s Esbriet and Boehringer Ingelheim’s Ofev. The simultaneous approvals set the stage for a commercial showdown.

ASCEND Data Puts InterMune’s Pirfenidone On Top

Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel